Logo

KLTO

Klotho Neurosciences, Inc.

KLTO

Klotho Neurosciences, Inc. • NASDAQ
$0.48 ▲ 5.60% (+0.03)
Market Cap $25.04 M
52w High $3.91
52w Low $0.11
Dividend Yield 0%
P/E -1.58
Volume 397.91K
Outstanding Shares 52.70M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.853M ▼ $-2.896M ▲ 0% $-0.049 ▲ $-1.718M ▲
Q2-2025 $0 $1.893M ▲ $-4.093M ▼ 0% $-0.12 ▼ $-2.333M ▼
Q1-2025 $0 $1.587M ▼ $-2.234M ▼ 0% $-0.081 ▼ $-1.68M ▲
Q4-2024 $0 $1.852M ▼ $-2.067M ▲ 0% $-0.076 ▲ $-1.771M ▲
Q3-2024 $0 $2.871M $-2.959M 0% $-0.18 $-2.914M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.348M ▼ $10.073M ▼ $145.891K ▼ $9.927M ▼
Q2-2025 $8.431M ▲ $10.846M ▲ $195.409K ▼ $10.65M ▲
Q1-2025 $565.869K ▲ $2.987M ▲ $2.349M ▲ $638.709K ▼
Q4-2024 $63.741K ▲ $2.457M ▼ $1.272M ▲ $1.185M ▼
Q3-2024 $50.895K $2.464M $1.004M $1.461M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.896M ▲ $-1.088M ▲ $0 $5.3K ▼ $-1.083M ▼ $-1.088M ▲
Q2-2025 $-4.093M ▼ $-1.968M ▼ $0 $9.834M ▲ $7.865M ▲ $-1.968M ▼
Q1-2025 $-2.234M ▼ $-1.554M ▼ $0 $2.056M ▲ $502.128K ▲ $-1.554M ▼
Q4-2024 $-2.067M ▲ $-944.154K ▲ $0 $957K ▲ $12.846K ▲ $-944.15K ▲
Q3-2024 $-2.959M $-1.073M $0 $278.518K $-794.441K $-1.073M

Five-Year Company Overview

Income Statement

Income Statement KLTO is a classic early‑stage biotech story: no product revenue yet and a small but growing operating loss as it begins to spend on development and public-company costs. The slight negative earnings show that the company has moved from being almost dormant financially to actually funding research, regulatory preparation, and corporate infrastructure. The core message: this is a science‑driven, pre‑commercial firm where expenses are an investment in future trials rather than being supported by ongoing sales.

Balance Sheet

Balance Sheet The reported balance sheet figures are essentially blank, which likely reflects limited or incomplete data rather than a company with literally no assets. From the narrative, KLTO appears to rely mainly on cash raised from investors, with little or no traditional debt and a relatively simple capital structure. Recent capital raises and restored listing compliance suggest the balance sheet has improved, but it is still likely lean and sensitive to market conditions. As with most small biotechs, long-term strength will depend on continued access to funding rather than on existing hard assets.

Cash Flow

Cash Flow Cash flow is typical of a development‑stage biotech: money flows out for research, manufacturing preparation, and overhead, with no operating cash inflows from product sales yet. Capital spending needs appear modest, as the company is more focused on intellectual property, clinical work, and outsourced manufacturing than on owning large facilities. The key watchpoint is cash burn versus available cash and funding options, since ongoing trials and new programs will steadily consume resources until there is either a partnership, licensing income, or eventual product approval.

Competitive Edge

Competitive Edge KLTO’s edge is built around a focused niche: an exclusive, worldwide license to a specific Klotho gene therapy platform, reinforced by a strong patent position and Orphan Drug status for its ALS candidate. This combination can create meaningful barriers to direct copycats and potential periods of market exclusivity if products are approved. At the same time, the company is very small and operates in crowded, high‑stakes fields such as Alzheimer’s and ALS, where it competes indirectly with much larger pharma and biotech players. Its position is therefore a mix of strong scientific differentiation and intellectual property, offset by scale disadvantages, execution risk, and heavy dependence on successful trial outcomes.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of KLTO. The company is developing gene therapies based on the Klotho “anti‑aging” pathway, using viral vectors to deliver a secreted form of the Klotho protein that could, in theory, provide long‑lasting neuroprotection with a single treatment. Two lead candidates target Alzheimer’s and ALS, both areas with urgent medical need and few effective options. Preclinical work and Orphan Drug designation suggest scientific promise, and partnerships for manufacturing plus a new research center in Japan show steady investment in capabilities. However, everything is still at a relatively early stage, so scientific, regulatory, and clinical risks remain very high until human trial data are available.

Summary

KLTO is an early-stage, pre‑revenue biotech focused on a novel gene-therapy approach to aging‑related brain diseases. Financially, it is in the typical position of such companies: modest but growing losses, a balance sheet built primarily on investor capital rather than operating cash flows, and a business model that depends on future trial success and continued financing. Strategically, it has an attractive scientific story, strong intellectual property, and regulatory advantages like Orphan Drug status, but it also faces the usual challenges of small biotechs: high development risk, long timelines, and competition from much larger firms. The company’s future will likely be shaped by three things: progress in clinical trials, its ability to secure partnerships and capital on reasonable terms, and how effectively it can expand its longevity platform while managing cash burn and execution risk.

NEWS

November 7, 2025 · 10:03 AM UTC

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Read more

October 16, 2025 · 8:00 AM UTC

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Read more

October 7, 2025 · 6:20 PM UTC

Klotho Neurosciences Announces Expiration of Letter of Intent

Read more

September 30, 2025 · 8:30 AM UTC

Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership

Read more